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Abstract
Although cloning and expression of T-cell Receptors (TcRs) has been performed for almost two decades, these procedures
are still challenging. For example, the use of T-cell clones that have undergone limited expansion as starting material to limit
the loss of interesting TcRs, must be weighed against the introduction of mutations by excess PCR cycles. The recent
interest in using specific TcRs for cancer immunotherapy has, however, increased the demand for practical and robust
methods to rapidly clone and express TcRs. Two main technologies for TcR cloning have emerged; the use of a set of
primers specifically annealing to all known TcR variable domains, and 59-RACE amplification. We here present an improved
59-RACE protocol that represents a fast and reliable way to identify a TcR from 10
5 cells only, making TcR cloning feasible
without a priori knowledge of the variable domain sequence. We further present a detailed procedure for the subcloning of
TcRa and b chains into an expression system. We show that a recombination-based cloning protocol facilitates simple and
rapid transfer of the TcR transgene into different expression systems. The presented comprehensive method can be
performed in any laboratory with standard equipment and with a limited amount of starting material. We finally exemplify
the straightforwardness and reliability of our procedure by cloning and expressing several MART-1-specific TcRs and
demonstrating their functionality.
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Introduction
Recently, T-cell receptors (TcRs) have gained interest as
attractive immunotherapeutics in cancer [1,2,3,4]. Proof-of-
concept for the effectiveness of cancer-targeted TcRs in man
was first demonstrated in malignant melanoma by Rosenberg et al.
[5]. Here, a TcR isolated from a patient with an efficient anti-
tumor response was transferred in vitro to T cells from patients that
did not mount such responses. Regression of metastatic melanoma
was observed in 2/15 TcR-treated patients, and the TcR-
transduced T cells could be detected 12 months after treatment.
These encouraging results have boosted the search for novel TcRs
with utility in cancer-treatment. However, although the cloning of
a murine [6] and a human [7] TcR was first performed almost
three decades ago, this procedure remains challenging thus
preventing rapid and widespread testing of novel TcRs for
therapeutic use. Since the mRNA levels encoding TcR in a T
cell are considerably lower compared with those encoding
immunoglobulin in a B cell, cloning of the former represents a
far bigger challenge when cell numbers are limited. Furthermore,
as the risk of inducing errors in the sequence increases relative to
the number of PCR cycles, it is advantageous to start with
thousands rather than hundreds of cells. However, when
expanding T-cell clones, a large fraction of the clones is invariably
lost and the corresponding TcRs made unavailable for further
testing. It is therefore desirable to have a method that allows the
accurate discovery of the TcR sequence from clones that count less
than a million T cells.
Among methods previously presented for TcR cloning, two
have gained particular popularity due to their low cost and
practicality. One method involves direct PCR amplification of T-
cell cDNA, using a panel of primers annealing to all Variable
regions of TcRs (V-region, more than 50 for TCRa and -b)
[8,9,10]. This method has been used to perform single cell TcR
cloning [11,12]. The other is a 59-RACE amplification. This
elegant method was presented almost two decades ago [13] and
was recently modified by other groups [14,15,16,17]. By tailing the
59-end of the total cDNA synthesized from a T-cell clone, TcRs
could be amplified specifically without a priori knowledge of the
identity of the V-region. This system was mainly restricted to
sequence identification and provided valuable information of the
TcR usage in a given cell line or clones. For many applications, it
is desirable to express the TcR following sequence identification.
Although the ectopic expression of TcR was accomplished 25
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27930years ago [18] and the method has evolved [19,20,21], only a few
examples of practical identification-expression interfaces have
been proposed [16,22].
In the present paper, we have improved the backbone of the 59-
RACE protocol for the identification of TcR sequences from a low
number of T cells, but without an excessive number of PCR cycles
to ensure accurate sequence identification. The TcR chains are
then amplified using V-chain specific primers. By overlapping
PCR, the TcR chains are linked using the picornavirus 2A peptide
coding sequence to generate a TcR_2A transgene [23]. The
somatic recombination at the CDR3 hypervariable domains, as
well as the variability in the sequences of the V region, may
generate restriction sites that complicate further subcloning. To
avoid the need for tailor made primers accommodating restriction
site requirements, we have developed a platform that exploits
TOPO-cloning and recombination systems. This universal
platform is a simple and rapid method to subclone any TcR_2A
transgene into different expression systems. Here, we validate this
method with MART-1 specific TcRs and show that they can be
transferred to retroviral- or RNA-vector systems for subsequent
expression and testing without extensive cloning design. The
detailed protocol described herein can be established in any
laboratory and represents a convenient method to isolate, identify,
and study TcRs of interest.
Results and Discussion
Determination of TCRa and b chain identity
TcRa and b mRNA have similar structures, consisting of a
constant 39-end and a variable 59-end. Upon translation they will
generate Type 1 receptor proteins where the constant domain will
cross the plasma membrane and provide the first half of the
extracellular domain, followed by the variable domain with the
hypervariable region CDR3 pointing at the top of the structure
(Fig. 1a). The unknown identity of the variable region makes
amplification of the receptor a challenge.
MART-1/Melan-A is overexpressed in melanoma and repre-
sents a well defined melanocyte marker used in diagnostics. A
peptide derived from MART-1/Melan-A (MART-1 peptide26–35,
ELAGIGILTV) that is presented by HLA-A2, has become a
widely used immunotherapeutic target, and TcRs recognizing this
complex have been isolated [24]. Our protocol was established
with CD8+ T-cell clone derived from a cell line specific for the
MART-1 peptide presented on HLA-A2. In a previous study, we
sorted T cells reactive with HLA-A2/MART-1 multimers as single
cells and expanded the resulting T-cell clones [25]. In the present
study, these T-cell clones were utilized as the starting material for
molecular cloning, using 10
5 T cells from each clone. This reduces
the loss of TcRs due to failure to adequately expand clones, while
limiting the number of PCR-introduced errors in the subsequent
cloning protocol. The RNA was prepared from fresh T cells
(primary clones or SupT1 cell line, see below) or frozen pellets (see
Materials and methods). The total RNA produced from these
clones was checked for purity and, depending on the yield, as little
as 300 ng was used to synthesize cDNA.
As shown in Fig. 1b, the polyA RNA was reverse-transcribed
using an oligodT primer. The quality of the resulting cDNA was
checked either by actin amplification or direct loading of the
cDNA onto an agarose gel (Fig. 2a). Since the identity of the TcR
V was unknown, a polynucleotide anchor was added to the cDNA
39-end of the V-domain side by tailing the purified cDNA with
cytosines using the Terminal-deoxynucleotide-Transferase (TdT)
in a 15 minute reaction (Fig. 1b). The tailed cDNA was then re-
purified and amplified in a semi nested PCR: the 2 PCR reactions
were performed using a modified poly-guanosine/inosine primer
(pGI) together with specific primers for the constant domains of
TcRa and b (pCa1/2 and pCb1/2, respectively; 1 for the first
PCR and 2 for the second). Inosine preferentially replaces
guanosine, but connects to cytosine with only two hydrogen
bonds [26]. Consequently the pGI primer will have a decreased
melting temperature during the PCR cycles. This represents an
advantage over the use of poly-guanosine primers. The first PCR
does not usually generate a visible gel fragment at the expected size
(around 500 bp for both TcRa and b), but rather a weak smear
(data not shown). This smear results from the different portions of
the 59-UTR that are reverse transcribed during cDNA synthesis as
well as from non-specific amplicons. Indeed, direct cloning of this
material provides only a few positive sequences for TcR and a
large amount of contaminating sequences (non-TcR cDNA, data
not shown). A second round of PCR using nested primers for the
C domains (pC2) was thus performed to generate a product of
higher specificity (Fig. 2b). Importantly, pCb-1 and pCb-2 are
specific for both TcRb isoforms since they were designed to anneal
on overlapping stretches (Table 1 and data not shown). As
expected, the second PCR generated a fragment of more than
450 bp in size. Smaller fragments will not contain the translation
start site. Again a smear was observed on agarose gel, but it mainly
consisted of specific bands as seen by subsequent sequencing. Since
the PCR reactions were performed using Taq polymerase, the gel-
purified amplicon could be cloned into a TA-opened plasmid. The
expected plasmid insert should contain the full V-chain, the CDR3
and a piece of the C-domain. Separate bacteria colonies were
picked from the same reaction. The sequences of 2 to 4 colonies
were then compared in order to identify eventual PCR-generated
errors. The identity of the sequenced insert was determined by
comparing the sequence of interest against the public IMGT
database ([27], http://imgt.cines.fr/). Therefore, even if the PCR
generated errors present in all sequences, the identification of the
correct V-gene would not be affected. Since identical TcR
sequences were sometimes found in different original T-cell clones
(sister clones), we here present 9 unique HLA-A2/MART-1
specific TcR sequences (Table 2). Some TcRa chains were not
sequenced but were analyzed with specific primers recognizing
TRAV12-2 only [25]. As reported in our previous study [25],
TcRs specific for allogeneic HLA-A2 in complex with the MART-
1 peptide showed a bias for TRAV12-2, in a similar way as TcRs
recognizing this complex in autologous setting. [28,29,30]
Our protocol was also tested on a commonly used T-cell line,
SupT1. SupT1 is derived from a lymphoma with a chromosomal
inversion that renders it TcRa negative [31], but is often wrongly
described as TcRab negative. We confirmed other reports
claiming that these cells express a functional TcRb [32], but also
found that they express TcRa mRNA encoding a non-functional
receptor (Table 2). As discussed below and by others [11], this type
of mRNA is often found during T-cell analysis. Importantly, as
seen for SupT1, 3 out of 9 MART-1 specific colonies possessed a
non-functional TcRa (not shown in Table 2) in agreement with
previous observations [11,33]. These non-functional TcRa chains
can lead to misinterpretations in the TcR V-region analysis
performed by PCR profile analysis, unless sequencing is
performed. The TcRb were also sequenced and did not show
any strong bias in the Vb usage (Table 2). Taken together we
present a straightforward protocol to analyze the sequence of
TcRs of interest from a low number of cells.
Subcloning of TcRab into a flexible expression system
An expression construct was designed by fusing TcRa and b
chains with a 2A sequence of picornavirus, a strategy described by
TcR Cloning and Expression
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promotes ribosomal skipping, thus allowing the release of the
upstream protein and translation of the downstream gene, which is
of interest in multicistronic expression vectors. Since somatic
recombinations at the hypervariable regions, and V domain
variations [37] may generate novel restriction sites that potentially
interfere with enzyme-based cloning, we exploited a recombina-
tion technology that permits the design of real universal primers
for any TcR V-domain (Table 1).
As shown in Fig. 3, the polyC-cDNA template generated for
sequence determination was also used for expression construct
amplification. The 2A sequence was fused to the TcRa and b
chains by overlapping PCR, using a high fidelity polymerase. The
Ca-2A primer is universal; it contains the complete 2A coding
sequence and removes the natural STOP of the TcRa. The
resulting 2A sequence is given in Fig. 3 and has some additional
features consisting of a furin site followed by an SGSG linker
upstream of the 2A peptide. The furin site is thought to remove the
Figure 1. TcR structure and cloning strategy. (a) TcRa and b mRNA structures are similar: The 59-situated Variable (V) domain encodes for the N-
terminal part of the extracellular domain (EC) of the TcR. It starts with the signal sequence (L) upstream of the V-region. It ends at the recombination
site with the D domain (only in TcRb) and Joining domain (J), representing the hypervariable CDR3 domain. On the 39-side of the messenger lies the
Constant (C) region, which encodes for the carboxy-terminal part of the EC, the transmembrane region (TM) and the short intracellular domain (IC).
(b) The 59-RACE of the TcR is performed by reverse-transcription of mRNA into cDNA using an oligo dT primer. The cDNA is then polyC-tailed by TdT
and this reaction is followed by two sequential amplifications using nested primers (pC1 and pC2) together with a polyC annealing primer (pGI). The
final product is cloned into pTA and sequenced. The sequenced portion results in the full length V-domain and the CDR3 if the tailing has occurred
on the 59-UTR.
doi:10.1371/journal.pone.0027930.g001
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acid extension (SGSG) has been shown to improve the production
of functional TcRs compared to the 2A sequence only, as
described in [34]. The 2A-Vb is unique and can be smaller than
the Ca-2A: an overlap of 27 nucleotides on the 2A side is sufficient
to generate a fusion product. The Va-primer is unique, and should
contain a CACC sequence before the ATG (59-end) to orient it for
the TOPO cloning. Finally, the Cb primers are also universal, but
specific for either TcRb of the C1 or C2 types. A restriction site
(here XhoI) can be added to these primers in order to verify the
cloning (Table 1). The final product is subcloned into a directional
entry-vector (pTOPO-ENTR) yielding pTOPO-TcRa-2A-TcRb
(pTOPO-TcR_2A).
Expression of TcR using different vectors
After sequencing of the pTOPO-TcR_2A, the insert can be
recombined into any type of expression vector without the need
for additional sequencing. Since TcR expression is mainly
performed by mRNA electroporation or retroviral transduction,
we converted different expression plasmids into Gateway
TM
destination vectors by adding a recombination cassette (see
Materials and Methods). We selected a validated mRNA
expression vector, pCIpA120 [38], and two retroviral vectors,
pMSGV [17] and pMP71 [39]. These modified vectors, named
pCIpA120-G, pMSGV-G and pMP71-G, respectively, are
destination vectors with cassettes that can be replaced by any
pENTR-containing insert in a one-step recombination.
We first wanted to investigate if the Gateway
TM cassette
modification potentially interfered with protein production. We
therefore subcloned a validated MART-1-specific TcR, DMF5
[40] into a pENTR vector and recombined it into the converted
pMSGV-G. SupT1 cells were transduced with the original
pMSGV-DMF5 construct in parallel with the Gateway
TM-
construct, pMSGV-G-DMF5. TcR expression efficiencies were
then compared by anti-TcRab staining and were shown to be
equal with both backbones (Fig. 4a). Co-staining of HLA-A2/
MART-1 multimer and anti-CD3 further demonstrated similar
levels of binding and expression. From these data, we concluded
that the addition of recombination sites did not interfere with TcR
expression (Fig. 4b).
Two in-house HLA-A2/MART-1 allo-restricted TcRs (B44 and
B60, bold in Table 2) were next compared to the DMF5 TcR. All
constructs were sub-cloned into the pMP71-G vector and
transduced into SupT1 cells to measure their expression and
binding efficiencies. As shown in Fig. 5a, all TcRs were expressed
(CD3 staining). The binding capacities were however different;
B60 seemed to require higher levels of TcRs on the surface for
multimer binding than DMF5, since cells staining with similar
levels of CD3 showed higher levels of multimer binding when
transduced with DMF5. Moreover, B44 was not able to bind
HLA-A2/MART-1 multimers, despite the fact that the original
clone was selected for its pentamer-binding ability [25]. The use of
Dasatinib, a SRC/ABL inhibitor shown to increase multimer
signal by preventing TcR internalization [41], did not restore B44
binding (data not shown). In contrast to SupT1 cells, Jurkat cells
can secrete IL-2 upon activation. Thus, by measuring IL-2 release
it was possible to monitor TcR activity. Importantly, we have
observed that TcR expression in our strain of Jurkat cells was
highly increased when the MP71 retroviral vector was used,
whereas SupT1 cells were not sensitive to the type of vector used
(data not shown). We therefore transduced Jurkat cells with the
MP71-constructs or a control construct (pMP-71-GFP). Seven
days after transduction, MART-1 specific TcR-expressing Jurkat
were incubated with HLA-A2 positive T2 cells, loaded or not with
MART-1 peptide. Detection of IL-2 release was performed by
ELISA (Fig. 5b). As shown, the three TcR constructs had a similar
capacity to stimulate Jurkat cells in a peptide dependent manner,
whereas Jurkat cells alone did not release IL-2 in any conditions.
Another attractive method to express TcRs is by mRNA
electroporation. We prepared mRNA in vitro using the pCIpA120-
G modified vector. Again, SupT1 were used to test the TcR
expression upon mRNA electroporation. The cells efficiently
expressed the three TcRs after 12 hours as measured by anti-CD3
staining (Fig. 6a). As seen with the retroviral transduction (Fig. 5a),
B44 did not react with the multimer whereas the other two
constructs were positive. Finally, PBMC were electroporated with
the mRNA of the three TcRs, and TcR activity was monitored
4.5 hours later. Redirected PBMC were incubated with T2 cells
loaded or not with MART-1 peptide. To evaluate activation of
CD8+ T-cells, degranulation was measured as expression of
CD107a/b [42]. As shown in Fig. 6b, CD8+ T cells expressing
DMF5 TcR were efficiently stimulated with peptide-loaded T2
cells. Although T cells expressing either of the two allogeneic TcRs
were also specifically stimulated, they were less efficient than
DMF5-expressing cells. As a control, all transduced cells were also
incubated with 1 mg/mL phytohemaglutinin (PHA) to verify that
Figure 2. TcR cloning. (a) Three T-cell clones (1–3) were used to
prepare total RNA. The mRNA was reverse-transcribed with oligo dT, as
described in Fig. 1, and 1/20 of the cDNA was loaded on the gel to
check reverse-transcription efficiency (upper gel). The same cDNAs were
amplified using actin primers annealing to two different exons and 1/20
was loaded on the gel (lower gel). As a negative control, the same
reaction was performed without template. (b) For the second PCR, 1/50
of the first PCR was amplified using a nested primer annealing to the 39-
end of the cDNA. When 1/10 of the PCR product was run on a 1.5%
agarose gel, a smeared product could be observed.
doi:10.1371/journal.pone.0027930.g002
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the cells. Taken together, the results show a discrepancy between
multimer staining and functional avidities, as B44, which did not
stain with multimers, induced higher functional responses than
B60, which was positive in multimer staining.
This phenomenon has been previously reported by the group of
Schendel [43]. They observed that peripheral blood lymphocytes
transduced with two different TcRs showing virtually identical
HLA-multimer staining frequencies and intensities, had a 100-fold
difference in the sensitivity for peptide recognition, as measured in
functional assays [43]. They concluded that there is no significant
correlation between multimer analysis and functional avidity.
Another explanation can be that DMF5 might be more efficient
at recruiting CD3. Indeed Ahmadi et al. [44] recently showed that
increased levels of CD3 by retroviral transduction of T cells
increases the expression and the signaling of a redirecting TcR. In
this report they showed that a TcR acquired the capacity to bind its
cognate pentamer only if CD3 was co-expressed. One can speculate
that TcRs B44 and B60 would gain activity with extra CD3.
Moreover, DMF5 is known to be CD8 independent [40], whereas
B60 is CD8 dependent for multimer staining (data not shown).
Although the B44-redirected T cells were not able to bind
multimers, the original clone T-cell clone B44 was selected for its
multimer binding capacity [25]. The TcR level of the original clone
was likely higher than following ectopic expression, and multimer
staining may require higher levels of TcRs. Nevertheless, the levels
obtained by retroviral transduction or mRNA electroporation were
sufficient to trigger a specific response in the functional assays.
Finally, a factor to take into account when comparing different
TcRs in a transient transfection setup is their stability. We
observed that B60 mRNA-transduced T cells showed a reduced
signaling ability upon stimulation by MART-1 peptide loaded T2
cells at 10 hours, compared to 4.5 hours, after electroporation
(Fig. 6b and data not shown), whereas DMF5 and B44 were more
stable (data not shown). It is therefore tempting to speculate that
B60 has a faster turn-over than DMF5 and B44.
These data suggest that multimer staining should always be
combined with a functional assay to confirm the expression and
specific activity of a receptor of interest.
Conclusion
The molecular cloning of a heterodimeric receptor is a complex
task. An improved method to reliably clone and express TcR from a
limited number of T cells is presented. The TcR analysis protocol can
easily be run in any laboratory without special equipment. Since the
tailing isperformed on cDNA, the time required to work with RNA is
limited, reducing the problem of RNA degradation. By using the last
generation of reverse transcriptase, and selected kits (see Materials
and Methods), we obtained an optimal production of cDNA.
Furthermore, with this procedure, there is no need to acquire a
library of Va and Vb-specific primers, as the few primers listed in
T a b l e2s u f f i c et oi d e n t i f ya n yT c R .
Following the identification of the TcRa and b identities, the
expression strategy was to use a 2A linker between the 2 chains
[23]. We have further developed this technique by integrating the
TcR_2A constructs in a recombination system (Gateway
TM
Table 1. List of primer sequences and their use and/or specificity.
Primer name: Sequence: Comment:
pCa1 59-AGTCAGATTTGTTGCTCCAGGCC-39 reverse primer for 1st TCRa
amplification
pCb1 59-TTCACCCACCAGCTCAGCTCC-39 reverse primer for 1st TCRb
amplification
pCa2 59-ATACGCGTTCTCTCAGCTGGTACACGG-39 reverse primer for 2nd TCRa
amplification
pCb2 59-ATACGCGTAGATCTCTGCTTCTGATGGC-39 reverse primer for 2nd TCRb
amplification
pGI
a 59-CACCGGGIIGGGIIGGGII-39 PolyGI with TOPO cloning sites
pCa-2A 59-TGGTCCAGGGTTCTCTTCCACGTCGCCGGCCTGCT-
TCAGCAGGCTGAAGTTGGTGGCGCCGCTGCCTCTCTTGGCTC-
TGCTGGACCACAGCCGCAGCG-39
Universal TcRa constant primer-2A
peptide
pVb-2A
b 59-GCCGGCGACGTGGAAGAGAACCCTGGACCA-(VBspecific) -39 Vb primer fusing the 2A sequence
pVa
b 59-CACC-(Vaspecific) -39 Va specific primer
pC-STOPb1 59-ATATCTCGAGTCAGAAATCCTTTCTCTTGAC-39 TcRb constant part Type 1 primer
pC-STOPb2 59-ATATCTCGAGCTAGCCTCTGGAATCCTTTC-39 TcRb constant part Type 2 primer
pVa12-2
c 59-CACCATGATGAAATCCTTGAGAGT-39 Va12-2 specific primer
pVb6-5
c 59-AGAGCCAAGAGAGCCACCAACTTCAGCCT-
GCTGAAGCAGGCCGGCGACGTGGAGGAGAACCCCGGTCCCA-
TGAGCATCGGCCTCCTGTGC-39
Vb6-5 specific primer
pVb28
c 59-AGAGCCAAGAGAGCCACCAACTTCAGC-
CTGCTGAAGCAGGCCGGCGACGTGGAGGAGAACCCCGGTCCC-
ATGGGAATCAGGCTCCTGTG-39
Vb28 specific primer
pActinF 59-GCTCCGGCATGTGCAA-39 Actin exon 2
pActinR 59-AGGATCTTCATGAGGTAGT-39 Actin exon 4
aI is desoxyinosine.
bThese primers are designed when clone sequence is known.
cSequence in italic is V-chain specific.
doi:10.1371/journal.pone.0027930.t001
TcR Cloning and Expression
PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e27930system). The main benefit is the universality of the primers used
and the independence of restriction sites, which might easily be
generated in hyper-variable regions. For versatile expression
applications, we demonstrate the advantage of a recombination-
based system that allows rapid switching of the TcR construct
between vectors, as illustrated by production of the same TcR by
use of an RNA-based system as well as a retroviral vector.
Materials and Methods
Antibodies and cell lines
The following antibodies were used: anti-humanTcR
(T10B9.1A-31) Phycoerythrin (PE), anti-CD3 (OKT-3) Pacific
Blue (PB), anti-CD8 (RPA-T8) PE, anti-CD107a (H4A3) Alexa
Fluor 647, anti-CD107b (H4B4) Alexa Fluor 647 (BD Biosciences,
Erembodegem, Belgium), HLA-A2/MART-1 multimer-PE or –
APC were either from ProImmune Ltd. (Oxford, UK) or prepared
in-house. Anti-CD3 Alexa Fluor 647 was labeled in-house. For
functional assay, Brefeldin A and Monensin A were from Sigma-
Aldrich (St. Louis, MO, USA.) MART-1 peptide26–35 (ELAGI-
GILTV) was from ProImmune.
SupT1 cells were a kind gift from M. Pule (University College
London, UK) and Jurkat cells constitutively expressing CD8 were
a kind gift from M. Nishimura (Medical University of South
Carolina, Charleston, SC, USA). Packaging Hek-Platinium (Hek-
P) cells were from Cell Biolabs (San Diego, CA, USA). SupT1 and
Jurkat cells were grown in RPMI-1640 (PAA, Paschung, Austria),
whereas Hek-P were grown in DMEM (PAA). All mediums were
supplemented with heat-inactivated 10% fetal calf serum (FCS,
HyClone, Logan, UT, USA) and 100 U/mL penicillin/strepto-
mycin (PAA). PBMC were isolated and maintained as described in
[25].
TcR cloning
T-cell clones counting at least 10
5 cells were stored as pellet at
280uC prior to RNA isolation (Fig. 1b). RNA was prepared using
Absolutely RNA Miniprep kit (Stratagene, La Jolla, CA, USA),
following the manufacturer’s recommendations. The RNA was
eluted in 50 mL elution buffer (pre-warmed at 65uC). The yield
varied from 10–200 ng/mL. The RNA was checked for quality
and quantity by Agilent 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, California) in the core facilities of Oslo University
Hospital Radiumhospitalet, Oslo, Norway. Preparation of cDNA
was performed using the maximum amount of RNA (from
100 ng). SuperScript
TM III Reverse Transcriptase (Invitrogen,
Carlsbad, CA, USA) was used following instructions, together with
oligodT primers (Invitrogen) and the addition of RNAsinH
(Stratagene) in the mix. The reaction was left for 1 hour at
50uC and RNAsin was inactivated at 60uC for 15 min. The mix
was then RNAseH treated (New England Biolabs, Ipswich, MA,
USA) at 37uC for 20 min. The cDNA was then precipitated:
22 mL cDNA+ 0.5 mL Glycogen (Fermentas, St. Leon-Rot,
Germany) + 1/10 V sodium acetate 3 M pH 5.6+2.5 V Et-OH
100%. This mix was incubated at 220uC for 20 min, spun down
for 10 min at 10,0006ga t4 uC, ethanol-70% washed and the dry
pellet resuspended in 11 mL dH2O. The 39 terminal dC tailing of
the cDNA was done in the following mix: 10 mL of the cDNA was
heated at 95uC for 1 min and chilled on ice before tailing. TdT
enzyme and buffer (Roche, Basel, Switzerland) were mixed with
dCTP and cDNA in a final Volume of 20 mL and incubated at
Table 2. TcR composition.
Origin V domain composition CDR3
SUPT-1 TcRa TRAV1-1 TRAJ12 - CAVPP
#MDSSYKLIF
TcRb TRBV9 TRBJ2-1 TRBD2 CASSVGGSLKQFF
B48 TcRa TRAV41 TRAJ49 - CAVNGTGNQFYF
TcRb TRBV27 TRBJ1-5 TRBD1 CASSFGGLGQPQHF
B1 TcRa TRAV12-2 TRAJ31 - CAVSNARLMF
TcRb TRBV2 TRBJ1-5 TRBD1 CASSDSGVGQPQHF
B11 TcRa nd nd - nd
TcRb TRBV2 TRBJ1-6 TRBD1 CASISFQRQAPNSPLHF
B44 TcRa TRAV12-2 TRAJ20 - CAVKVYKLSF
TcRb TRBV6-5 J1-2 TRBD1 CASSSPNRQGDYGYTF
B54 TcRa TRAV4 TRAJ40 - CLVGSASGTYKYIF
TcRb TRBV4-1 TRBJ1-5 TRBD1 CASSQDPGLHQPQHF
B60 TcRa TRAV12-2 TRAJ23-1 - CAAQGGKLIF
TcRb TRBV28 TRBJ1-3 - CASSPVGLSGNTIYF
B36 TcRa TRAV12 nd - nd
TcRb TRBV6-2 TRBJ1-1 TRBD1 CASSYLGQPTLNSANTGELFF
B9 TcRa TRAV12 nd - nd
TcRb TRBV4-2 TRBJ1-1 TRBD1 CASSPGPLLTEAFF
#: frameshift.
nd: not determined.
doi:10.1371/journal.pone.0027930.t002
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precipitated as previously described and re-suspended in 24 mL
dH2O.
V chain amplification was performed in two steps (Fig. 1b). All
PCR reactions were performed with Titanium Polymerase
(Clontech, Saint-Germain-en-Laye, France) and the primers
Figure 3. TcR_2A cloning strategy. Full length TcRa and b were re-amplified from cDNA using specific primers in 2 separate PCR reactions: The
TcRa STOP codon was removed and a 2A coding sequence is fused to its 39-end (pCa-2A). At the 59-end of the TcRa, a CACC sequence was fused to
the ATG to generate a Kozak sequence and also to orient the fragment for TOPO cloning (pVa). TcRb was amplified using a forward primer that fused
the 2A sequence in frame with its ATG (pVb-2A). The reverse primer (pC-STOPb1/2) contains the STOP codon. Importantly, the forward primers (Va
and Vb specific) were designed to anneal the signal sequence (L) to the V region. The second PCR was overlapping and run using gel purified
fragments of the two TcR chains and the external primers (pVa and pC-STOPb1/2). The amplicon was finally cloned into a TOPO-directional vector in
order to generate pTOPO-TcR_2A. This vector possesses recombination sites that can be used for recombination into expression vectors.
doi:10.1371/journal.pone.0027930.g003
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Germany). The first PCR was performed with the following
primers: pCa1 and pGI (TcRa) and pCb1 and pGI (TcRb) under
these conditions: 25 cycles (19 94uC, 19 53uC and 19 68uC). The
second PCR was nested. It was performed with the following
primers: pCa2 and pGI (TcRa) and pCb1 and pGI (TcRb) under
these conditions: 20 cycles (19 94uC, 19 53uC and 309 68uC).
The amplicons were gel purified with E.Z.N.A. Cycle-pure Kit
(Omega Bio-Tek Inc., Norcross, GA, USA) and finally cloned into
pGEM vector using TA cloning technology (Promega, Madison,
WI, USA). Clonings from low amounts of starting material were
selected with blue/white screen. Colonies were picked, EcoRI
(New England Biolabs) cut to monitor insert size and sent for
sequencing (Eurofins MWG Operon) using M13rev(229) and
M13uni(221) primers provided by the vendor. Sequences were
analyzed online and named according to IMGT database (http://
imgt.cines.fr/).
TcR_2A construct cloning
All PCRs were performed using Pfx polymerase (Invitrogen). A
first PCR was run to separately amplify TcRa and b (Fig. 3) using
pVa and pCa-2A (TcRa) and pVb-2A with pC-STOPb1/2
(TcRb, Table 1) with the following conditions: 25 cycles (19 94uC,
19 53uC and 19 68uC). The amplicons were run on an agarose gel
and bands were purified (Omega Bio-Tek Inc.) for the second
PCR. An equimolar amount (estimated on gel) of the fragments
were mixed together with pVa and pC-STOPb1/2 and the PCR
was run under these conditions: 20 cycles (19 94uC, 19 53uC and 29
68uC). The product was then cloned into pTOPO-ENTR vector
(Invitrogen). DNA was extracted from 4 different Kanamycin
resistant colonies and sequenced (Eurofins MWG Operon), using
pTOPO primers (M13rev(229) and M13uni(221)) and a pair of
internal primers: pCb2 and pCa2. Positive constructs were
subcloned by recombination in any destination vector (see text),
following manufacturer’s instructions.
The construct pMSGV-DMF5_2A was a kind gift from R.
Morgan (NIH, Bethesda, USA).
Conversion to Destination vector
pDEST-51 (Invitrogen) was used as a template for amplification
of the Gateway
TM cassette and ligated into pGEM by TA cloning.
Ten ng of pDEST-51 was amplified with the following primers: 59-
ATA TAC AAT TGA GGG TTA GGG ATA GGC TTA C-39
and 59-ATA TCT CGA GTA ATA CGA CTC ACT ATA GGG-
39, using Pfx for 25 cycles (19 94uC, 19 53uC and 29 68uC). TA-
overhang was added using 7 mL clean PCR product together with
Figure 4. Validation of the recombination-system. (a) SupT1 cells were transduced with the indicated retroviral supernatant or mock-
transduced (grey) by spinoculation and cultured for 2 days. They were then washed and stained with anti-TcR-PE and analyzed by flowcytometry.
DMF5 inserted into MSGV or MSGV-G vectors resulted in comparable expression. (b) Three days post-transduction, SupT1 were co-stained with anti-
CD3 PB and HLA-A2/MART-1 multimer-APC. SupT1 transduced with an irrelevant TcR were used as a multimer negative control. The percentage of
cells is shown in each quadrant.
doi:10.1371/journal.pone.0027930.g004
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KCl set at pH 8.3), 1 mL Taq and 1 mL dATP (2 mM) at 70uC for
30 min and ligated 1 hr at room temperature (RT) with T4 ligase
(Promega), dialyzed against dH2O and 2 mL of this was
electroporated in DB3.1 (resistant to the suicide gene, ccdB) on
ampicilin/chlorophenicol plate. This construct was sequenced and
used to further subclone the cassette. The conversion of pMSGV
(a kind gift from R. Morgan, NIH, Bethesda, USA) was done by
XhoI/EcoRI or MunI digestion. The conversion of pMP71 (a kind
gift from W. Uckert, Berlin, Germany), was performed by blunting
a NotI site in pMP71 and inserting the gateway cassette by blunt
and EcoRI or MunI digestion. The cloning of pCIpA120-G was
perfomed using the same enzymes as for pMSGV.
Retroviral particle preparation and transduction
Supernatants were prepared in Hek-P cells. Briefly, 1.2610
6
Hek-P were plated in 6 cm plates. Transfection was performed
using Fugene-6 (Roche) with a mix of DNA including the retroviral
packaging vectors and the expression vector to an equimolar ratio.
After 24 hours, cells were transferred to a 32uC incubator and
medium was replaced with 1% FCS containing DMEM. Superna-
tants were harvested after 24 and 48 hours incubation.
Transduction of SupT1 and Jurkat cells was done as follows:
2.5610
5 cells in a 12-well non-treated culture plate pre-coated
with 0.5 mL/well Retronectin (20 mg/mL, Takara Bio. Inc.,
Shiga, Japan) were spinoculated with 1 mL of retroviral
supernatant at 9006g for 60 min at 32uC. After 2 days, cells
were harvested with PBS-EDTA 0.5 mM and grown in RPMI-
10%FCS.
mRNA preparation and electroporation
DNA plasmid was used as a template, it was opened with MfeI
(New England Biolabs), which lies downstream of the polyA tail
[38]. Small scale mRNA was prepared using the mMESSAGE
mMACHINEH T7 kit (Ambion, Austin, TX, USA) following
manufacturer’s instructions.
TcR expression analysis
Around 10
5 cells were resuspended in a solution containing the
indicated antibody or multimer at 10 mg/mL for 20 min at RT.
Cells were washed twice with Flow buffer (PBS, 2% FCS, 0.5 mM
EDTA), and analyzed using LSR II flow cytometer (BD
Biosciences). Figures were prepared using FlowJo software (Tree
Star Inc., Ashland, OR, USA).
Figure 5. Retroviral delivery of MART-1 specific TcRs. (a) B44, B60 and DMF5 TcR_2A were expressed in the pMP71-G vector and transduced
into SupT1 cells. After 3 days, cells were co-stained with anti-CD3 PB and HLA-A2/MART-1 multimer-PE. (b) Jurkat cells were transduced with the same
constructs as in (a) or with a GFP pMP71-vector (Mock) and incubated for 24 hours with T2 cells loaded with or without MART-1 peptide (10 mM final
concentration). IL-2 release was monitored by ELISA assay, and plotted as pg of IL-2 per mL of medium. Each bar represents the mean values of
duplicates. Similar results were observed in two separate experiments.
doi:10.1371/journal.pone.0027930.g005
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(CD107a/b) were performed as described in [25]. Expanded T
cells were electroporated at 7.5 mg mRNA/1 million cells in BTX
ECM 830 (BTX, Harvard Apparatus, Holliston, MA, USA)
square-wave electroporator in 2 mm cuvettes at 250 V for 2 ms.
Cells were immediately grown at 1 million/mL CellGro DC
medium (CellGenix, Freiburg, Germany) containing 5% human
serum and 100 U IL-2 (Peprotech EC Ltd., London, United
Kingdom)/mL pre-warmed at 37uC. Electroporated T cells were
subsequently incubated at 37uC for 3 hr. After that the medium
was changed and IL-2 removed for 1.5 hours before addition of
the target cells.
IL-2 ELISA was performed following manufacturer’s procedure
(R&D Systems, Abingdon, United Kingdom).
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